The software specializes in the rapid quantitative analysis of MRI scans, identifying markers of brain atrophy and white matter degeneration. By detecting structural changes associated with Alzheimer’s disease and vascular dementia, the platform generates personalized reports to assist clinicians in diagnostic accuracy. This deployment builds upon existing research ties Neurophet established with institutions including the National University of Singapore and the Dementia Research Centre at Nanyang Technological University.

Raffles Medical currently operates a network exceeding 100 clinics, supported by Raffles Hospital and various specialist centers. Co-CEO Jake Junkil Been noted that the collaboration aims to solidify the company's clinical footprint in the region. Founded in 2016, Neurophet focuses on AI-driven tools for brain disorder diagnosis and treatment planning, with a product portfolio that includes specialized monitoring software for Alzheimer’s and Multiple Sclerosis.